KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Current Leases (2019 - 2025)

Novartis Ag's Current Leases history spans 7 years, with the latest figure at $263.0 million for Q4 2025.

  • For Q4 2025, Current Leases rose 11.91% year-over-year to $263.0 million; the TTM value through Dec 2025 reached $263.0 million, up 11.91%, while the annual FY2025 figure was $263.0 million, 11.91% up from the prior year.
  • Current Leases for Q4 2025 was $263.0 million at Novartis Ag, up from $235.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $275.0 million in Q4 2021 and bottomed at $230.0 million in Q4 2023.
  • The 5-year median for Current Leases is $251.0 million (2022), against an average of $250.8 million.
  • The largest annual shift saw Current Leases dropped 8.73% in 2022 before it rose 11.91% in 2025.
  • A 5-year view of Current Leases shows it stood at $275.0 million in 2021, then decreased by 8.73% to $251.0 million in 2022, then decreased by 8.37% to $230.0 million in 2023, then rose by 2.17% to $235.0 million in 2024, then grew by 11.91% to $263.0 million in 2025.
  • Per Business Quant, the three most recent readings for NVS's Current Leases are $263.0 million (Q4 2025), $235.0 million (Q4 2024), and $230.0 million (Q4 2023).